Bone densitometry vendor Lunar last month announced that its third-quarter revenues would likely decline compared with the same quarter last year. Lunar of Madison, WI, pointed to below-average sales of densitometers in the U.S. and Asia as a reason for
Bone densitometry vendor Lunar last month announced that its third-quarter revenues would likely decline compared with the same quarter last year. Lunar of Madison, WI, pointed to below-average sales of densitometers in the U.S. and Asia as a reason for the anticipated down quarter (end-March 31).
While the company attributed the dip in Asian sales to the region's recent currency difficulties, U.S. demand has been shifting away from traditional hospital markets toward lower priced systems for physician offices. In an effort to improve access to these emerging markets, Lunar is implementing new distribution channels. The company expects to soon announce new national distributor relationships for its existing physician-office products, as well as its Achilles ultrasound densitometer, which is pending Food and Drug Administration premarket approval.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.